Gregory Pastores

List of Publications by Year
in descending order

23 papers	1,684 citations	686830 13 h-index	752256 20 g-index
23 all docs	23 docs citations	23 times ranked	1447 citing authors

#	Article	IF	Citations
1	Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine, 2002, 113, 112-119.	0.6	491
2	The Gaucher Registry. Archives of Internal Medicine, 2000, 160, 2835.	4.3	451
3	Clinical course of sly syndrome (mucopolysaccharidosis type VII). Journal of Medical Genetics, 2016, 53, 403-418.	1.5	133
4	Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1. JAMA - Journal of the American Medical Association, 2015, 313, 695.	3.8	120
5	Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. Journal of Pediatrics, 2004, 144, 112-120.	0.9	107
6	Outcomes after 18 months of eliglustat therapy in treatmentâ€•naÃ¯ve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trial. American Journal of Hematology, 2017, 92, 1170-1176.	2.0	77
7	Association Between Progranulin and Gaucher Disease. EBioMedicine, 2016, 11, 127-137.	2.7	72
8	High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 2010, 33, 291-300.	1.7	47
9	Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 47-53.	0.6	45
10	Presenting signs and patient coâ€•variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GEDâ€•C) Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.5	39
11	Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells, Molecules, and Diseases, 2018, 71, 71-74.	0.6	27
12	Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. Recent Patents on CNS Drug Discovery, 2006, 1, 77-82.	0.9	20
13	Pharmacological treatment of pediatric Gaucher disease. Expert Review of Clinical Pharmacology, 2018, 11, 1183-1194.	1.3	20
14	Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. Molecular Genetics and Metabolism, 2019, 128, 62-67.	0.5	13
15	Scintigraphic evaluation of Tcâ€•99mâ€•lowâ€•density lipoprotein (LDL) distribution in patients with Gaucher disease. Clinical Genetics, 1997, 52, 7-11.	1.0	6
16	The genetic and biochemical basis of trimethylaminuria in an Irish cohort. JIMD Reports, 2019, 47, 35-40.	0.7	5
17	Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease. Pediatric Health, Medicine and Therapeutics, 2017, Volume 8, 73-81.	0.7	4
18	Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.. Blood, 2009, 114, 1349-1349.	0.6	3

#	Article	IF	Citations
19	IMPACT study: measuring the impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland. Therapeutic Advances in Rare Disease, 2021, 2, 263300402110207.	0.3	2
20	Management of patients with Gaucher's disease: Clinical perspectives. European Journal of Internal Medicine, 2006, 17, S9-S12.	1.0	1
21	Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells, Molecules, and Diseases, 2019, 77, 101-102.	0.6	1
22	PO099â€...Autosomal dominant gene negative frontotemporal dementia-think sca17. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A37.4-A38.	0.9	0
23	P627â€...Mitochondrial disease mimics. , 2019, , .		0